{"id":4302,"date":"2018-01-10T13:10:52","date_gmt":"2018-01-10T12:10:52","guid":{"rendered":"http:\/\/kreftgenomikk.w.uib.no\/?page_id=4302"},"modified":"2019-01-21T19:26:50","modified_gmt":"2019-01-21T18:26:50","slug":"om-oss","status":"publish","type":"page","link":"https:\/\/kreftgenomikk.w.uib.no\/en\/om-oss\/","title":{"rendered":"About us"},"content":{"rendered":"

[et_pb_section admin_label=”Seksjon” fullwidth=”on” specialty=”off”][et_pb_fullwidth_post_title admin_label=”Fullbreddes innleggstittel” title=”on” meta=”off” author=”on” date=”on” categories=”on” comments=”on” featured_image=”on” featured_placement=”background” parallax_effect=”off” parallax_method=”on” text_orientation=”right” text_color=”light” text_background=”on” text_bg_color=”rgba(21,150,137,0.9)” module_bg_color=”rgba(255,255,255,0)” title_font=”|on|||” title_font_size=”35px” title_all_caps=”off” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_id=”header-image-and-text”]<\/p>\n

 <\/p>\n

[\/et_pb_fullwidth_post_title][\/et_pb_section][et_pb_section admin_label=”Seksjon” fullwidth=”off” specialty=”off”][et_pb_row admin_label=”Rad”][et_pb_column type=”2_3″][et_pb_text admin_label=”Tekst” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Norwegian Cancer Genomics Consortium (NCGC) consists of clinicians and specialised cancer research groups, situated at the Norwegian University Hospitals. The participants collaborate on two large research projects, focused on cancer genomics. The projects, which have received 75 M NOK in funding from the Norwegian Research Council, aim to establish new clinical practises for cancer treatment. The projects are led by the associated group leaders, Tom D\u00f8nnem (UNN), Bj\u00f8rn Tore Gjertsen (HUS), Jutta Heix (Oslo Cancer Cluster), Harald Holte (OUS), Eivind Hovig (OUS), Ragnhild Lothe (OUS), Per Eystein L\u00f8nning (HUS), Leonardo Meza-Zepeda (OUS), Ola Myklebost (OUS), Sissel Rogne (Bioteknologir\u00e5det), Ole Morten Seternes (UiT), Jan Helge Solbakk (UiO, vara Sissel Rogne), Giske Ursin (KR), Anders Waage (St Olav). Eyrun Thune is the coordinator.<\/h4>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Contacts (title)” background_layout=”dark” text_orientation=”left” background_color=”#108271″ use_border_color=”off” border_color=”#ffffff” border_style=”solid” text_line_height=”2em” custom_padding=”10px|5px|5px|5px”]<\/p>\n

Contacts<\/h4>\n

[\/et_pb_text][et_pb_text admin_label=”Contacts” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

\"\"<\/p>\n

Ola Myklebost<\/h4>\n

Professor, Project leader<\/em><\/p>\n

ola@kreftgenomikk.no<\/a><\/p>\n

+47 5558 4565<\/p>\n

 <\/p>\n

\"\"<\/p>\n

Liv Cecilie Vestrheim Thomsen<\/h4>\n

Co-ordinator<\/em><\/p>\n

liv@kreftgenomikk.no<\/a><\/p>\n

+47 909 35 449<\/p>\n

[\/et_pb_text][et_pb_divider admin_label=”Skillelinje” color=”#ffffff” show_divider=”off” divider_style=”solid” divider_position=”top” hide_on_mobile=”on”]<\/p>\n

 <\/p>\n

[\/et_pb_divider][et_pb_text admin_label=”The Project Leadership (title)” background_layout=”dark” text_orientation=”left” background_color=”#108271″ use_border_color=”off” border_color=”#ffffff” border_style=”solid” text_line_height=”1.9em” custom_padding=”10px|5px|5px|5px”]<\/p>\n

The Governing Board<\/h4>\n

[\/et_pb_text][et_pb_text admin_label=”The Project Leadership” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Erlend B Smeland<\/strong><\/h4>\n

Professor, Forskningsdriekt\u00f8r OUS, – Styreleder<\/em><\/p>\n

 <\/p>\n

J\u00f3nas Einarsson<\/strong><\/h4>\n

Direkt\u00f8r Radiumhospitalets forskningsstiftelse<\/em><\/p>\n

 <\/p>\n

Anne Sameline Grimsgaard<\/strong><\/h4>\n

Professor, Forskningsdekan UNN\/UiT<\/em><\/p>\n

 <\/p>\n

Bj\u00f8rn Gustafsson<\/strong><\/h4>\n

Professor, Forskningsdekan StOlav\/NTNU<\/em><\/p>\n

 <\/p>\n

Tove Flem Jacobsen<\/strong><\/h4>\n

VP Science & Regulatory at Aker BioMarine Antarctic<\/em><\/p>\n

 <\/p>\n

Edvin W Johannesen<\/strong><\/h4>\n

Seniorr\u00e5dgiver – Forskningsadministrasjon UiO<\/em><\/p>\n

 <\/p>\n

Olav Mella<\/strong><\/h4>\n

Professor, Avdelingssjef Haukeland\/UiB<\/em><\/p>\n

 <\/p>\n

Knut Martin Torgersen<\/strong><\/h4>\n

Medisinsk r\u00e5dgiver Pfizer<\/em><\/p>\n

[\/et_pb_text][et_pb_text admin_label=”Partners” background_layout=”dark” text_orientation=”left” background_color=”#108271″ use_border_color=”off” border_color=”#ffffff” border_style=”solid” text_line_height=”1.9em” custom_padding=”10px|5px|5px|5px”]<\/p>\n

Health service priority area<\/strong><\/h4>\n

[\/et_pb_text][et_pb_image admin_label=”Bilde” src=”http:\/\/kreftgenomikk.no\/files\/2013\/11\/logo.png” show_in_lightbox=”off” url=”http:\/\/kreftsatsing.no” url_new_window=”on” use_overlay=”off” animation=”off” sticky=”off” align=”left” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

 <\/p>\n

[\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

[et_pb_section admin_label=”Seksjon” fullwidth=”on” specialty=”off”][et_pb_fullwidth_post_title admin_label=”Fullbreddes innleggstittel” title=”on” meta=”off” author=”on” date=”on”...<\/p>\n","protected":false},"author":4078,"featured_media":457,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4302","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/4302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/users\/4078"}],"replies":[{"embeddable":true,"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=4302"}],"version-history":[{"count":40,"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/4302\/revisions"}],"predecessor-version":[{"id":5839,"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/4302\/revisions\/5839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/media\/457"}],"wp:attachment":[{"href":"https:\/\/kreftgenomikk.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=4302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}